05.14.24 -- Nothing To See Here! Just Big Pharma Investments In China

The World Health Organization (WHO) recently released a document titled Benefits and risks of using artificial intelligence for pharmaceutical development and delivery describing the ethical issues and governance considerations for using AI in drug discovery, preclinical development, and clinical trials.

Delve into the intricacies of a successful CDMO relationship and learn how a collaborative approach built on shared goals and open communication can maximize the potential of your cell therapy program.

Learn about the distinction between gene therapy and gene editing, as well as the therapeutic potential of CRISPR treatments and the challenges associated with clinical trials and commercialization.

Nucleic acid drugs hold the potential to target diseases by harnessing the power of DNA and RNA. Explore how strategic partnerships are enabling the transformative possibilities of these drugs.

In this episode of The Business of Biotech, hear experts discuss the importance of increasing specialized CDMO capacity for cell and gene therapy applications.

Learn more about the platform-based scalable suspension process for LVV production and how it is impacting CGTs advancing toward commercialization.

It is crucial to ensure that Cell & Gene Therapy (CGT) supply chain risks are mitigated, as well as to have proactive strategies in place to address unforeseen challenges before they become an issue.

Discover a ready-to-use, suspension-based platform technology for transient transfection of LVVs that eliminates the need to transition from small-scale adherent processes.

Review how to develop and use QC assays that can facilitate both product and process understanding and control.

Introducing our new Fill/Finish session! Outsourced Pharma Capacity Update’s new PARTNER WEEK offers an extended schedule and sessions grouped by capability including a day featuring the latest sterile filling, lyophilization, and advanced packaging technologies from CDMOs with current capacity for your manufacturing demands. Secure your spot for this session happening May 20th.

Browse this brochure full of information on manufacturing grades, services, validation, and more that Vernal Biosciences can support.

Looking for scalability in clinical manufacturing? Andelyn Biosciences' current Good Manufacturing Practices (cGMP) Clinical Manufacturing Facility operates according to FDA cGMP Guidelines and with multinational health agencies around the world.

Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.